Biocon Q1 performance to remain in focus

| Updated on July 23, 2014


Biocon is declaring its April-June quarter performance on Thursday. Analysts expect consolidated net profit to grow 27-32 per cent year-on-year to ₹110-135 crore. Consolidated revenue is seen growing 20 per cent at ₹830 crore. The management had indicated in the annual report a greater investment in R&D, enhance operating efficiencies with a focus on product launches and licensing opportunities. Developments on those front will remain in focus.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on July 23, 2014
This article is closed for comments.
Please Email the Editor